Less: imputed interest

  
The following table presents the maturity of the Company’s operating lease liabilities as of December 31, 2021 ($ in millions):

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |
| 2022 | $ | 232  |  |
| 2023 | 190  |  |
| 2024 | 160  |  |
| 2025 | 130  |  |
| 2026 | 105  |  |
| Thereafter | 400  |  |
| Total operating lease payments | 1,217  |  |
| Less: imputed interest | (121) |  |
| Total operating lease liabilities | $ | 1,096  |  |

As of December 31, 2021, the Company had no additional significant operating or finance leases that had not yet commenced.  
NOTE 11. GOODWILL AND OTHER INTANGIBLE ASSETS As discussed in Note 2, goodwill arises from the purchase price for acquired businesses exceeding the fair value of tangible and intangible assets acquired less assumed liabilities and noncontrolling interests. Management assesses the goodwill of each of its reporting units for impairment at least annually at the beginning of the fourth quarter and as “triggering” events occur that indicate that it is more likely than not that an impairment exists. The Company elected to bypass the optional qualitative goodwill assessment allowed by applicable accounting standards and performed a quantitative impairment test for all reporting units as this was determined to be the most effective method to assess for impairment across the reporting units. The Company estimates the fair value of its reporting units primarily using a market approach, based on current trading multiples of EBITDA for companies operating in businesses similar to each of the Company’s reporting units, in addition to recent available market sale transactions of comparable businesses. In determining the estimated fair value of each reporting unit, the Company also applies a control premium. If the estimated fair value of the reporting unit is less than its carrying value, the Company must perform additional analysis to determine if the reporting unit’s goodwill has been impaired.As of December 31, 2021, the Company had five reporting units for goodwill impairment testing. As of the date of the 2021 annual impairment test, the carrying value of the goodwill included in each individual reporting unit ranged from $515 million to approximately $31.6 billion. No goodwill impairment charges were recorded for the years ended December 31, 2021, 2020 and 2019 and no “triggering” events have occurred subsequent to the performance of the 2021 annual impairment test. The factors used by management in its impairment analysis are inherently subject to uncertainty. If actual results are not consistent with management’s estimates and assumptions, goodwill and other intangible assets may be overstated and a charge would need to be taken against net earnings.The following is a rollforward of the Company’s goodwill by segment ($ in millions):  

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | LifeSciences |  | Diagnostics |  | Environmental & Applied Solutions |  | Total |
| Balance, January 1, 2020 | $ | 13,472  |  |  | $ | 6,901  |  |  | $ | 2,340  |  |  | $ | 22,713  |  |
| Attributable to 2020 acquisitions | 10,291  |  |  | —  |  |  | 111  |  |  | 10,402  |  |
| Attributable to 2020 divestitures | (181) |  |  | —  |  |  | —  |  |  | (181) |  |
| Adjustments due to finalization of purchase price allocations | (3) |  |  | —  |  |  | —  |  |  | (3) |  |
| Foreign currency translation and other | 2,233  |  |  | 181  |  |  | 75  |  |  | 2,489  |  |
| Balance, December 31, 2020 | 25,812  |  |  | 7,082  |  |  | 2,526  |  |  | 35,420  |  |
| Attributable to 2021 acquisitions | 7,077  |  |  | 110  |  |  | 48  |  |  | 7,235  |  |
| Attributable to 2021 divestitures | —  |  |  | —  |  |  | (12) |  |  | (12) |  |
| Adjustments due to finalization of purchase price allocations | (11) |  |  | —  |  |  | —  |  |  | (11) |  |
| Foreign currency translation and other | (1,240) |  |  | (148) |  |  | (60) |  |  | (1,448) |  |
| Balance, December 31, 2021 | $ | 31,638  |  |  | $ | 7,044  |  |  | $ | 2,502  |  |  | $ | 41,184  |  |

The increase in the goodwill balance of the Life Sciences segment in the year ended December 31, 2021 is primarily a result of the Aldevron Acquisition. Refer to Note 2 for more detail. 89
